NCX-6560 is a HMG-CoA reductase inhibitor and nitric oxide donor potentially for the treatment of atherosclerosis and dyslipidemia. NCX-6560 reduced portal pressure without changing systemic hemodynamics. NCX-6560 induced a higher intrahepatic vasoprotective profile. NCX-6560 eliminated hepatic toxicity and reduced muscular toxicity caused by atorvastatin. References: Momi S, Impagnatiello F, Guzzetta M, Caracchini R, Guglielmini G, Olivieri R, Monopoli A, Gresele P. NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. Eur J Pharmacol. 2007 Sep 10;570(1-3):115-24. PubMed PMID: 17632098.

纯度：≥98%

CAS：803728-45-2